Intercell

Defunct biotechnology company in Austria

Intercell AG

Company type| Aktiengesellschaft

Traded as

| WBAG: ICLL
OTCQX: INRLY
Industry| Biotechnology
Founded| 1998
Defunct| 2013 (2013)
Fate| Merged with Vivalis SA
Successor| Valneva SE
Headquarters|

Vienna

Austria

Key people

| Thomas Lingelbach (CEO), Michel Gréco (Chairman of the supervisory board)
Products| Development of vaccines
Revenue| €34.2 million (2010)[1]

Operating income

|  (€251.2 million) (2010)[1]

Net income

|  (€255.2 million) (2010)[1]
Total assets| €225.2 million (end 2010)[1]
Total equity| €121.1 million (end 2010)[1]

Number of employees

| 410 (average, 2010)[1]
Website| www.intercell.com

Intercell AG was a biotechnology company based in Vienna which focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases. The company merged with Vivalis to form Valneva SE in 2012.[2] Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology (IMP) in Vienna.[3] It employs 400 people in Austria, Scotland and the United States.

## History

[edit]

It was founded in 1998 and focused on the research, development, and commercialization of vaccines and other biological products. Intercell AG's products were used to prevent and treat a variety of infectious diseases, including hepatitis B, Japanese encephalitis, and pneumonia. In 2012, Intercell AG merged with Vivalis SE, a French biotech company, to form Valneva.[4]

It has been listed on the Vienna Stock Exchange since February 28, 2005. In 2008, Intercell signaled its intent to acquire Maryland-based Iomai, a developer of needle-free vaccination technology.[5][6]

Intercell cooperates with pharmaceutical companies like Novartis, Merck and Sanofi-Aventis on vaccine production.

The most important projects of Intercell are:

* Vaccine against Japanese encephalitis (approved in Europe, America and Australia)[7][8][9]

* Therapeutic vaccine against hepatitis C (in clinical phase II)[10]
* Antigen identification program and adjuvant technologies.
* Vaccine Enhancement Patch to improve prevention against pandemic influenza (in collaboration with U.S. Department of Health and Human Services, in clinical phase II)

## References

[edit]

1. ^ a b c d e f "Annual Report 2010" (PDF). Intercell. Archived from the original (PDF) on 26 June 2011. Retrieved 3 May 2011.
2. ^ Carroll, John (17 December 2012). "Troubled Intercell throws in the towel, signs off on merger deal with Vivalis". Fierce Biotech. Retrieved 27 January 2018.
3. ^ "Research Institute of Molecular Pathology (IMP) - About the IMP > History". Research Institute of Molecular Pathology. Retrieved 2009-07-25. [dead link]
4. ^ "The Dark Horse of the Vaccine Race May Be This French Biotech". Bloomberg.com. 2021-04-29. Retrieved 2023-01-09.
5. ^ Fox, Maggie; Grenon, Andre (2008-05-12). "Austrian vaccine maker Intercell buys Iomai". Reuters. Archived from the original on 2011-06-20. Retrieved 2008-08-15.
6. ^ Staff (1 June 2008), "Intercell to Acquire Iomai for $189M", Genetic Engineering & Biotechnology News, News: Inside Industry, vol. 28, no. 11, Mary Ann Liebert, Inc., p. 14, ISSN 1935-472X
7. ^ "Intercell's Japanese Encephalitis Vaccine FDA approval". Medical News Today. 2009-03-31. Retrieved 2009-03-31. [dead link]
8. ^ "Intercell's Japanese Encephalitis Vaccine EMEA approval for Europe". Intercell. 2009-04-02. Retrieved 2009-04-02. [dead link]
9. ^ "Intercell's Japanese Encephalitis Vaccine Australian TGA approval". Intercell. 2009-01-23. Retrieved 2009-01-23. [dead link]
10. ^ "Intercell Hepatitis C Vaccine Meets Primary Endpoints". FDA News. 2007-08-22. Retrieved 2008-08-15.

## External links

[edit]

* Official website

* Companies portal

This article on an Austrian company is a stub. You can help Wikipedia by expanding it.

|

* v
* t
* e

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template